Prevention of oral candidiasis during radiotherapy for head and neck cancer by orabi

Multicenter interventional study of effects of Orabi on prevention of oral candidiasis during radiotherapy for head and neck cancer - Prevention of oral candidiasis during radiotherapy for head and neck cancer by orabi

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071190023

Enrollment

Registered

2019-09-03

Start date

2020-04-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck cancer head and neck cancer, oral candidiasis

Interventions

Orabi group: Orabi is administrated when grade II oral mucositis developed.

Oral candidiasis, radiotherapy, prophylaxis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with head and neck cancer undergoing radiotherapy

Exclusion criteria

Exclusion criteria: Patients with problem in judgement

Design outcomes

Primary

Measure	Time frame
Development of oral candidiasis	—

Secondary

Measure	Time frame
Development of grade 3 oral mucositis, period until healing of oral candidiasis, investigation of factors related to development of oral candidiasis	—

Contacts

Public ContactSakiko Soutome

Nagasaki University Hospital

sakiko@nagasaki-u.ac.jp+81-95-819-7663

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026